| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Radiosurgery | 39 | 2024 | 289 | 11.630 |
Why?
|
| Lung Neoplasms | 21 | 2024 | 2367 | 3.080 |
Why?
|
| Breast Neoplasms | 25 | 2023 | 3015 | 2.870 |
Why?
|
| Neoplasms | 30 | 2024 | 3079 | 2.530 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 12 | 2023 | 1122 | 2.180 |
Why?
|
| Neoplasm Metastasis | 23 | 2024 | 1115 | 2.020 |
Why?
|
| Radiotherapy | 13 | 2020 | 334 | 1.820 |
Why?
|
| Antibodies, Monoclonal, Humanized | 8 | 2023 | 973 | 1.670 |
Why?
|
| Radiation Oncology | 12 | 2023 | 121 | 1.670 |
Why?
|
| Chemoradiotherapy | 4 | 2021 | 309 | 1.320 |
Why?
|
| Combined Modality Therapy | 28 | 2024 | 1720 | 1.250 |
Why?
|
| Radiotherapy, Intensity-Modulated | 12 | 2021 | 176 | 1.220 |
Why?
|
| Anus Neoplasms | 4 | 2009 | 36 | 1.160 |
Why?
|
| Brain Neoplasms | 10 | 2023 | 784 | 1.120 |
Why?
|
| Clinical Clerkship | 7 | 2018 | 118 | 1.120 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 18 | 2021 | 185 | 1.100 |
Why?
|
| Humans | 119 | 2024 | 89630 | 0.980 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 12 | 2024 | 2568 | 0.840 |
Why?
|
| Biomarkers, Tumor | 3 | 2021 | 1555 | 0.810 |
Why?
|
| Antineoplastic Agents, Immunological | 3 | 2020 | 202 | 0.800 |
Why?
|
| Radiotherapy Dosage | 17 | 2021 | 470 | 0.760 |
Why?
|
| Radiotherapy, Conformal | 6 | 2020 | 84 | 0.750 |
Why?
|
| Antibodies, Monoclonal | 4 | 2024 | 1412 | 0.740 |
Why?
|
| Disease-Free Survival | 9 | 2022 | 1217 | 0.700 |
Why?
|
| Female | 53 | 2024 | 46361 | 0.700 |
Why?
|
| Transforming Growth Factor beta | 2 | 2023 | 324 | 0.690 |
Why?
|
| Carcinoma, Squamous Cell | 8 | 2012 | 1098 | 0.680 |
Why?
|
| Immunotherapy | 10 | 2024 | 689 | 0.670 |
Why?
|
| Curriculum | 6 | 2018 | 568 | 0.670 |
Why?
|
| Radiobiology | 1 | 2018 | 13 | 0.620 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2018 | 57 | 0.610 |
Why?
|
| Prognosis | 13 | 2022 | 3796 | 0.590 |
Why?
|
| Aged, 80 and over | 21 | 2024 | 6834 | 0.580 |
Why?
|
| Genetic Therapy | 4 | 2007 | 370 | 0.570 |
Why?
|
| Mastectomy | 3 | 2017 | 246 | 0.550 |
Why?
|
| T-Lymphocytes | 3 | 2021 | 1226 | 0.550 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2017 | 841 | 0.540 |
Why?
|
| Middle Aged | 34 | 2024 | 26069 | 0.540 |
Why?
|
| Glioblastoma | 5 | 2020 | 265 | 0.540 |
Why?
|
| Aged | 33 | 2024 | 19237 | 0.530 |
Why?
|
| Phenanthridines | 5 | 2000 | 24 | 0.530 |
Why?
|
| Apoptosis | 8 | 2021 | 1720 | 0.520 |
Why?
|
| Career Choice | 2 | 2014 | 148 | 0.510 |
Why?
|
| Viruses | 3 | 2007 | 78 | 0.500 |
Why?
|
| Ceramides | 4 | 2000 | 35 | 0.490 |
Why?
|
| Antineoplastic Agents | 8 | 2021 | 2415 | 0.490 |
Why?
|
| Cranial Irradiation | 1 | 2014 | 40 | 0.480 |
Why?
|
| Protein Kinase C | 5 | 2000 | 268 | 0.460 |
Why?
|
| Radiation Injuries | 6 | 2020 | 162 | 0.450 |
Why?
|
| Treatment Outcome | 17 | 2023 | 8274 | 0.440 |
Why?
|
| Adult | 32 | 2024 | 26699 | 0.420 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 2 | 2014 | 116 | 0.410 |
Why?
|
| Interferon Type I | 2 | 2024 | 186 | 0.400 |
Why?
|
| Radiodermatitis | 1 | 2011 | 10 | 0.400 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2012 | 103 | 0.390 |
Why?
|
| Survival Rate | 8 | 2024 | 1909 | 0.390 |
Why?
|
| Radiation-Sensitizing Agents | 4 | 2001 | 97 | 0.380 |
Why?
|
| Prostatic Neoplasms | 4 | 2021 | 1780 | 0.380 |
Why?
|
| Male | 33 | 2024 | 42561 | 0.370 |
Why?
|
| Head and Neck Neoplasms | 6 | 2009 | 1063 | 0.370 |
Why?
|
| Prospective Studies | 9 | 2024 | 4311 | 0.360 |
Why?
|
| B7-H1 Antigen | 3 | 2024 | 278 | 0.350 |
Why?
|
| Students, Medical | 5 | 2016 | 421 | 0.350 |
Why?
|
| Breast | 1 | 2011 | 292 | 0.340 |
Why?
|
| Statistics as Topic | 1 | 2010 | 234 | 0.340 |
Why?
|
| Clinical Trials, Phase III as Topic | 3 | 2019 | 176 | 0.330 |
Why?
|
| Gastrointestinal Tract | 2 | 2021 | 191 | 0.330 |
Why?
|
| MicroRNAs | 4 | 2016 | 556 | 0.330 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2018 | 3461 | 0.330 |
Why?
|
| Program Evaluation | 6 | 2018 | 308 | 0.320 |
Why?
|
| Pneumonia | 2 | 2022 | 183 | 0.320 |
Why?
|
| Obesity | 2 | 2014 | 972 | 0.320 |
Why?
|
| Ipilimumab | 2 | 2021 | 62 | 0.310 |
Why?
|
| Comorbidity | 2 | 2020 | 951 | 0.310 |
Why?
|
| Liver Neoplasms | 3 | 2024 | 761 | 0.310 |
Why?
|
| Fluorouracil | 7 | 2009 | 560 | 0.300 |
Why?
|
| Mitomycin | 4 | 2009 | 29 | 0.300 |
Why?
|
| RNA-Binding Proteins | 3 | 2024 | 277 | 0.290 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2008 | 159 | 0.280 |
Why?
|
| Cell Survival | 4 | 2019 | 983 | 0.280 |
Why?
|
| Radiation, Ionizing | 4 | 2021 | 123 | 0.280 |
Why?
|
| Radiotherapy, Adjuvant | 3 | 2017 | 296 | 0.280 |
Why?
|
| Enzyme Inhibitors | 6 | 2018 | 645 | 0.270 |
Why?
|
| Patient Selection | 3 | 2022 | 684 | 0.270 |
Why?
|
| Neoplasm Proteins | 2 | 2021 | 541 | 0.260 |
Why?
|
| Bone Marrow | 1 | 2007 | 445 | 0.260 |
Why?
|
| Pituitary Neoplasms | 1 | 2006 | 69 | 0.260 |
Why?
|
| Sphingomyelin Phosphodiesterase | 4 | 2000 | 21 | 0.260 |
Why?
|
| Proportional Hazards Models | 4 | 2020 | 856 | 0.250 |
Why?
|
| Clinical Competence | 3 | 2018 | 785 | 0.250 |
Why?
|
| Gene Expression Profiling | 4 | 2020 | 1436 | 0.250 |
Why?
|
| Bevacizumab | 5 | 2021 | 289 | 0.250 |
Why?
|
| Naphthalenes | 4 | 1999 | 45 | 0.250 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2021 | 618 | 0.250 |
Why?
|
| Dacarbazine | 2 | 2015 | 102 | 0.240 |
Why?
|
| Follow-Up Studies | 7 | 2021 | 3671 | 0.230 |
Why?
|
| Neoplasm Recurrence, Local | 6 | 2021 | 1366 | 0.230 |
Why?
|
| Program Development | 2 | 2015 | 123 | 0.230 |
Why?
|
| Melanoma | 2 | 2023 | 470 | 0.230 |
Why?
|
| Myeloid-Derived Suppressor Cells | 1 | 2024 | 26 | 0.230 |
Why?
|
| Animals | 21 | 2024 | 27428 | 0.230 |
Why?
|
| Melanoma, Experimental | 1 | 2024 | 111 | 0.230 |
Why?
|
| Radiotherapy, Image-Guided | 2 | 2016 | 58 | 0.230 |
Why?
|
| Radioimmunotherapy | 1 | 2023 | 27 | 0.220 |
Why?
|
| Mice | 14 | 2024 | 11792 | 0.220 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2024 | 66 | 0.220 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2024 | 112 | 0.210 |
Why?
|
| Adenocarcinoma | 5 | 2012 | 1201 | 0.210 |
Why?
|
| Neoplasm Staging | 7 | 2024 | 2023 | 0.210 |
Why?
|
| Radiometry | 3 | 2014 | 56 | 0.210 |
Why?
|
| Tomography, X-Ray Computed | 6 | 2020 | 2665 | 0.210 |
Why?
|
| Radiation Pneumonitis | 1 | 2022 | 21 | 0.210 |
Why?
|
| Dose-Response Relationship, Radiation | 3 | 2018 | 188 | 0.200 |
Why?
|
| Skin | 2 | 2016 | 585 | 0.200 |
Why?
|
| Neoplasms, Second Primary | 3 | 2015 | 260 | 0.200 |
Why?
|
| Anetoderma | 1 | 2021 | 2 | 0.200 |
Why?
|
| Receptors, Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2021 | 7 | 0.200 |
Why?
|
| Re-Irradiation | 1 | 2021 | 15 | 0.200 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2014 | 317 | 0.190 |
Why?
|
| Loss of Function Mutation | 1 | 2021 | 46 | 0.190 |
Why?
|
| Mastectomy, Segmental | 3 | 2011 | 101 | 0.190 |
Why?
|
| Dendritic Cells | 1 | 2024 | 450 | 0.190 |
Why?
|
| Erythroid Precursor Cells | 1 | 2021 | 33 | 0.190 |
Why?
|
| Exanthema | 1 | 2021 | 40 | 0.190 |
Why?
|
| Membrane Proteins | 2 | 2024 | 1225 | 0.190 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2021 | 112 | 0.190 |
Why?
|
| Benzophenanthridines | 5 | 2000 | 23 | 0.190 |
Why?
|
| Tumor Microenvironment | 2 | 2023 | 467 | 0.180 |
Why?
|
| Alkaloids | 5 | 2000 | 46 | 0.180 |
Why?
|
| Butyrates | 1 | 2021 | 46 | 0.180 |
Why?
|
| Gliosarcoma | 1 | 2020 | 7 | 0.180 |
Why?
|
| Cytochrome c Group | 1 | 2000 | 83 | 0.180 |
Why?
|
| Memantine | 1 | 2020 | 10 | 0.180 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2020 | 79 | 0.170 |
Why?
|
| Patient Care Management | 1 | 2020 | 30 | 0.170 |
Why?
|
| Critical Pathways | 1 | 2020 | 37 | 0.170 |
Why?
|
| Motivation | 1 | 2022 | 296 | 0.170 |
Why?
|
| Risk Factors | 4 | 2018 | 5516 | 0.170 |
Why?
|
| NF-kappa B | 1 | 2023 | 466 | 0.170 |
Why?
|
| Sphingomyelins | 2 | 1996 | 16 | 0.170 |
Why?
|
| National Cancer Institute (U.S.) | 2 | 2016 | 73 | 0.170 |
Why?
|
| Time Factors | 6 | 2020 | 5344 | 0.170 |
Why?
|
| Retrospective Studies | 8 | 2023 | 9091 | 0.170 |
Why?
|
| Body Mass Index | 2 | 2014 | 774 | 0.170 |
Why?
|
| Tumor Burden | 4 | 2017 | 308 | 0.170 |
Why?
|
| Down-Regulation | 2 | 2017 | 520 | 0.170 |
Why?
|
| Internship and Residency | 3 | 2018 | 1048 | 0.170 |
Why?
|
| Motion | 2 | 2017 | 93 | 0.160 |
Why?
|
| Programmed Cell Death 1 Receptor | 2 | 2018 | 173 | 0.160 |
Why?
|
| Glioma | 1 | 2021 | 294 | 0.160 |
Why?
|
| Sphingosine | 2 | 1997 | 74 | 0.160 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2018 | 864 | 0.160 |
Why?
|
| Cells, Cultured | 4 | 2017 | 2884 | 0.160 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2019 | 172 | 0.160 |
Why?
|
| Cone-Beam Computed Tomography | 2 | 2020 | 63 | 0.160 |
Why?
|
| Organs at Risk | 4 | 2021 | 40 | 0.160 |
Why?
|
| Palliative Medicine | 1 | 2018 | 11 | 0.160 |
Why?
|
| Mediastinum | 1 | 2018 | 47 | 0.160 |
Why?
|
| Breath Holding | 1 | 2018 | 23 | 0.160 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 131 | 0.160 |
Why?
|
| Regression Analysis | 2 | 2011 | 590 | 0.160 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2019 | 137 | 0.150 |
Why?
|
| Astrocytoma | 1 | 2018 | 82 | 0.150 |
Why?
|
| United States | 11 | 2018 | 7021 | 0.150 |
Why?
|
| Educational Measurement | 2 | 2018 | 231 | 0.150 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2018 | 102 | 0.150 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2018 | 58 | 0.150 |
Why?
|
| Feasibility Studies | 3 | 2021 | 783 | 0.150 |
Why?
|
| Neoplasms, Experimental | 1 | 2019 | 269 | 0.150 |
Why?
|
| Radiation Oncologists | 1 | 2017 | 14 | 0.150 |
Why?
|
| Societies, Scientific | 1 | 2017 | 43 | 0.150 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2018 | 146 | 0.140 |
Why?
|
| Education, Medical, Graduate | 2 | 2018 | 395 | 0.140 |
Why?
|
| Craniocerebral Trauma | 1 | 1997 | 56 | 0.140 |
Why?
|
| Transcription Factors | 2 | 2023 | 1657 | 0.140 |
Why?
|
| Credentialing | 1 | 2016 | 14 | 0.140 |
Why?
|
| Cell Line, Tumor | 7 | 2024 | 2565 | 0.140 |
Why?
|
| Isoenzymes | 1 | 1997 | 274 | 0.140 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2014 | 490 | 0.140 |
Why?
|
| Germ-Line Mutation | 1 | 2019 | 348 | 0.130 |
Why?
|
| Hippocampus | 1 | 2020 | 448 | 0.130 |
Why?
|
| Selection Bias | 1 | 2016 | 37 | 0.130 |
Why?
|
| Lymph Nodes | 2 | 2014 | 549 | 0.130 |
Why?
|
| Benchmarking | 1 | 2016 | 79 | 0.130 |
Why?
|
| Terminology as Topic | 1 | 2017 | 221 | 0.130 |
Why?
|
| Mammography | 2 | 2010 | 474 | 0.130 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2016 | 81 | 0.130 |
Why?
|
| Standard of Care | 1 | 2016 | 65 | 0.130 |
Why?
|
| Biopsy | 2 | 2018 | 1185 | 0.130 |
Why?
|
| Cognition | 1 | 2020 | 579 | 0.120 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2015 | 78 | 0.120 |
Why?
|
| Teaching | 1 | 2016 | 147 | 0.120 |
Why?
|
| Disease Management | 1 | 2017 | 329 | 0.120 |
Why?
|
| Radiotherapy Setup Errors | 1 | 2014 | 2 | 0.120 |
Why?
|
| Tumor Cells, Cultured | 5 | 2000 | 1057 | 0.120 |
Why?
|
| Lymphocytes | 1 | 1997 | 471 | 0.120 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 319 | 0.120 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 304 | 0.120 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2015 | 138 | 0.120 |
Why?
|
| Benzimidazoles | 1 | 2015 | 111 | 0.120 |
Why?
|
| Needs Assessment | 2 | 2014 | 157 | 0.120 |
Why?
|
| Guidelines as Topic | 1 | 2015 | 160 | 0.120 |
Why?
|
| Robotics | 1 | 2017 | 269 | 0.120 |
Why?
|
| Medical Oncology | 1 | 2018 | 384 | 0.120 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2017 | 261 | 0.120 |
Why?
|
| Boston | 1 | 2014 | 37 | 0.110 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2021 | 511 | 0.110 |
Why?
|
| Pandemics | 1 | 2020 | 775 | 0.110 |
Why?
|
| Gene Transfer Techniques | 3 | 2001 | 153 | 0.110 |
Why?
|
| Pediatrics | 1 | 2018 | 357 | 0.110 |
Why?
|
| Patient Positioning | 1 | 2014 | 65 | 0.110 |
Why?
|
| Consumer Behavior | 1 | 2014 | 31 | 0.110 |
Why?
|
| Metal Nanoparticles | 2 | 2010 | 31 | 0.110 |
Why?
|
| Hodgkin Disease | 1 | 2015 | 181 | 0.110 |
Why?
|
| Gold | 2 | 2010 | 41 | 0.110 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2018 | 539 | 0.110 |
Why?
|
| Bone Neoplasms | 1 | 2016 | 329 | 0.110 |
Why?
|
| Hospitals, Teaching | 1 | 2014 | 118 | 0.110 |
Why?
|
| Central Nervous System | 1 | 2014 | 153 | 0.110 |
Why?
|
| Young Adult | 8 | 2018 | 6350 | 0.110 |
Why?
|
| Data Interpretation, Statistical | 1 | 2014 | 300 | 0.100 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2013 | 215 | 0.100 |
Why?
|
| Carcinoma | 1 | 2016 | 443 | 0.100 |
Why?
|
| Cohort Studies | 3 | 2023 | 2881 | 0.100 |
Why?
|
| Child | 4 | 2018 | 7198 | 0.100 |
Why?
|
| Enzyme Activation | 3 | 2000 | 698 | 0.100 |
Why?
|
| Analysis of Variance | 2 | 2012 | 900 | 0.100 |
Why?
|
| Eye Neoplasms | 1 | 2012 | 27 | 0.100 |
Why?
|
| Neurosurgical Procedures | 1 | 2014 | 233 | 0.100 |
Why?
|
| Lung | 3 | 2014 | 1266 | 0.100 |
Why?
|
| Radiography, Thoracic | 1 | 2014 | 324 | 0.100 |
Why?
|
| Child, Preschool | 2 | 2016 | 3743 | 0.100 |
Why?
|
| Carcinoma, Large Cell | 1 | 2012 | 39 | 0.100 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2012 | 142 | 0.100 |
Why?
|
| Myeloid Cells | 2 | 2023 | 100 | 0.100 |
Why?
|
| Relative Biological Effectiveness | 2 | 2008 | 13 | 0.100 |
Why?
|
| Spinal Cord Neoplasms | 1 | 2012 | 48 | 0.100 |
Why?
|
| Clinical Trials as Topic | 3 | 2017 | 1152 | 0.100 |
Why?
|
| Risk Assessment | 2 | 2020 | 2306 | 0.100 |
Why?
|
| Organ Size | 1 | 2011 | 370 | 0.090 |
Why?
|
| Positron-Emission Tomography | 1 | 2012 | 337 | 0.090 |
Why?
|
| Deoxyglucose | 1 | 2010 | 36 | 0.090 |
Why?
|
| Reproducibility of Results | 5 | 2018 | 2763 | 0.090 |
Why?
|
| Pyrans | 1 | 2010 | 10 | 0.090 |
Why?
|
| Acetamides | 1 | 2010 | 26 | 0.090 |
Why?
|
| Mortality | 1 | 2011 | 149 | 0.090 |
Why?
|
| Mice, Nude | 3 | 2010 | 818 | 0.090 |
Why?
|
| Prodrugs | 2 | 2001 | 50 | 0.090 |
Why?
|
| Genes, p53 | 2 | 2001 | 110 | 0.090 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2009 | 37 | 0.090 |
Why?
|
| Surveys and Questionnaires | 4 | 2018 | 2641 | 0.090 |
Why?
|
| X-Ray Microtomography | 1 | 2010 | 91 | 0.090 |
Why?
|
| Signal Transduction | 2 | 2023 | 3393 | 0.090 |
Why?
|
| Adaptive Immunity | 2 | 2021 | 167 | 0.090 |
Why?
|
| Clinical Trials, Phase I as Topic | 2 | 2024 | 156 | 0.080 |
Why?
|
| Infant | 1 | 2016 | 3167 | 0.080 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2010 | 157 | 0.080 |
Why?
|
| Tamoxifen | 1 | 2010 | 168 | 0.080 |
Why?
|
| Chicago | 1 | 2014 | 1428 | 0.080 |
Why?
|
| Ethanolamines | 2 | 2000 | 24 | 0.080 |
Why?
|
| Oleic Acids | 2 | 2000 | 26 | 0.080 |
Why?
|
| Radiotherapy, Computer-Assisted | 1 | 2008 | 25 | 0.080 |
Why?
|
| Genetic Vectors | 2 | 2001 | 446 | 0.080 |
Why?
|
| Antibiotics, Antineoplastic | 2 | 1999 | 118 | 0.080 |
Why?
|
| Contrast Media | 2 | 2010 | 1092 | 0.080 |
Why?
|
| Endocannabinoids | 2 | 2000 | 31 | 0.080 |
Why?
|
| Cisplatin | 2 | 2007 | 618 | 0.080 |
Why?
|
| Radiation Dosage | 2 | 2023 | 227 | 0.080 |
Why?
|
| Cell Proliferation | 2 | 2013 | 1654 | 0.070 |
Why?
|
| Respiratory Mechanics | 1 | 2008 | 102 | 0.070 |
Why?
|
| Leukopenia | 1 | 2007 | 66 | 0.070 |
Why?
|
| Transplantation, Heterologous | 2 | 2000 | 370 | 0.070 |
Why?
|
| Mice, Knockout | 2 | 2024 | 2003 | 0.070 |
Why?
|
| Pelvis | 1 | 2007 | 96 | 0.070 |
Why?
|
| Recurrence | 1 | 2010 | 1144 | 0.070 |
Why?
|
| Neutropenia | 1 | 2007 | 216 | 0.070 |
Why?
|
| Cell Division | 2 | 2000 | 696 | 0.070 |
Why?
|
| Carboplatin | 2 | 2024 | 312 | 0.070 |
Why?
|
| Actins | 1 | 2010 | 460 | 0.070 |
Why?
|
| Drug Synergism | 2 | 1999 | 306 | 0.070 |
Why?
|
| Models, Statistical | 1 | 2010 | 576 | 0.070 |
Why?
|
| Anemia | 1 | 2007 | 130 | 0.070 |
Why?
|
| Thrombocytopenia | 1 | 2007 | 187 | 0.070 |
Why?
|
| Stereotaxic Techniques | 1 | 2006 | 80 | 0.070 |
Why?
|
| Phantoms, Imaging | 1 | 2009 | 451 | 0.070 |
Why?
|
| Disease Models, Animal | 3 | 2024 | 2377 | 0.070 |
Why?
|
| Disease Progression | 3 | 2018 | 1492 | 0.070 |
Why?
|
| Age Factors | 1 | 2010 | 1874 | 0.060 |
Why?
|
| Lymphatic Metastasis | 3 | 2016 | 503 | 0.060 |
Why?
|
| Algorithms | 4 | 2018 | 1890 | 0.060 |
Why?
|
| ErbB Receptors | 2 | 2023 | 501 | 0.060 |
Why?
|
| Biomarkers | 3 | 2022 | 1770 | 0.060 |
Why?
|
| Interferon-gamma | 2 | 2019 | 451 | 0.060 |
Why?
|
| Postoperative Care | 2 | 2017 | 232 | 0.060 |
Why?
|
| Chemokine CXCL10 | 1 | 2024 | 23 | 0.060 |
Why?
|
| Thoracic Wall | 2 | 2014 | 25 | 0.060 |
Why?
|
| Histones | 1 | 2006 | 331 | 0.060 |
Why?
|
| Etoposide | 1 | 2024 | 206 | 0.060 |
Why?
|
| Predictive Value of Tests | 1 | 2008 | 1728 | 0.060 |
Why?
|
| Salvage Therapy | 1 | 2004 | 236 | 0.060 |
Why?
|
| Software | 2 | 2017 | 666 | 0.060 |
Why?
|
| Lymph Node Excision | 1 | 2005 | 220 | 0.050 |
Why?
|
| Bile Duct Neoplasms | 1 | 2004 | 90 | 0.050 |
Why?
|
| Stomach Neoplasms | 1 | 2006 | 287 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 2 | 2021 | 3225 | 0.050 |
Why?
|
| Heart | 2 | 2018 | 574 | 0.050 |
Why?
|
| Palliative Care | 1 | 2004 | 264 | 0.050 |
Why?
|
| Quality of Life | 2 | 2021 | 1673 | 0.050 |
Why?
|
| Technology, Radiologic | 2 | 2016 | 104 | 0.050 |
Why?
|
| Models, Biological | 1 | 2008 | 1767 | 0.050 |
Why?
|
| Fatigue | 1 | 2021 | 179 | 0.050 |
Why?
|
| Vancomycin | 1 | 2021 | 73 | 0.050 |
Why?
|
| Microscopy, Electron, Transmission | 2 | 2010 | 136 | 0.040 |
Why?
|
| Prone Position | 1 | 2020 | 57 | 0.040 |
Why?
|
| Antiparkinson Agents | 1 | 2020 | 15 | 0.040 |
Why?
|
| Risk Management | 1 | 2020 | 43 | 0.040 |
Why?
|
| Permeability | 1 | 2000 | 138 | 0.040 |
Why?
|
| Placebos | 1 | 2020 | 214 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2011 | 472 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2021 | 682 | 0.040 |
Why?
|
| Interdisciplinary Communication | 1 | 2020 | 131 | 0.040 |
Why?
|
| Cytokines | 1 | 2023 | 804 | 0.040 |
Why?
|
| Photochemotherapy | 1 | 1999 | 101 | 0.040 |
Why?
|
| Infection Control | 1 | 2020 | 122 | 0.040 |
Why?
|
| Self-Assessment | 1 | 2018 | 47 | 0.040 |
Why?
|
| Radiation Tolerance | 1 | 2019 | 173 | 0.040 |
Why?
|
| Body Weight | 1 | 2000 | 452 | 0.040 |
Why?
|
| Training Support | 1 | 2018 | 23 | 0.040 |
Why?
|
| Interdisciplinary Studies | 1 | 2018 | 20 | 0.040 |
Why?
|
| Spirometry | 1 | 2018 | 66 | 0.040 |
Why?
|
| Pancreatic Neoplasms | 1 | 2004 | 683 | 0.040 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2020 | 565 | 0.040 |
Why?
|
| Chi-Square Distribution | 1 | 2018 | 360 | 0.040 |
Why?
|
| Cognition Disorders | 1 | 2020 | 234 | 0.040 |
Why?
|
| Survival Analysis | 2 | 2015 | 1535 | 0.040 |
Why?
|
| Nerve Tissue Proteins | 1 | 2021 | 512 | 0.040 |
Why?
|
| Ceramidases | 1 | 1997 | 4 | 0.040 |
Why?
|
| Advisory Committees | 1 | 2017 | 90 | 0.040 |
Why?
|
| Amidohydrolases | 1 | 1997 | 18 | 0.040 |
Why?
|
| Virus Replication | 1 | 1999 | 324 | 0.040 |
Why?
|
| Reference Standards | 1 | 2017 | 144 | 0.040 |
Why?
|
| Immunity, Innate | 1 | 2021 | 430 | 0.040 |
Why?
|
| Endopeptidases | 1 | 1997 | 118 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2014 | 2017 | 0.040 |
Why?
|
| Linear Models | 2 | 2009 | 421 | 0.040 |
Why?
|
| Betacoronavirus | 1 | 2020 | 261 | 0.040 |
Why?
|
| Head | 1 | 2017 | 137 | 0.040 |
Why?
|
| Bacteria | 1 | 2021 | 481 | 0.030 |
Why?
|
| Gene Expression Regulation | 2 | 2023 | 1977 | 0.030 |
Why?
|
| Respiration | 1 | 2018 | 266 | 0.030 |
Why?
|
| Proton Therapy | 1 | 2016 | 32 | 0.030 |
Why?
|
| Diffusion of Innovation | 1 | 2016 | 71 | 0.030 |
Why?
|
| Mitochondria | 1 | 2000 | 553 | 0.030 |
Why?
|
| Hydrolysis | 1 | 1996 | 141 | 0.030 |
Why?
|
| Costs and Cost Analysis | 1 | 2016 | 153 | 0.030 |
Why?
|
| Research Personnel | 1 | 2016 | 71 | 0.030 |
Why?
|
| Stomach | 1 | 2016 | 111 | 0.030 |
Why?
|
| Artifacts | 1 | 2017 | 247 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2020 | 1722 | 0.030 |
Why?
|
| Deception | 1 | 2015 | 20 | 0.030 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2014 | 599 | 0.030 |
Why?
|
| Cell Movement | 1 | 2019 | 785 | 0.030 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 1998 | 417 | 0.030 |
Why?
|
| Competitive Behavior | 1 | 2015 | 29 | 0.030 |
Why?
|
| School Admission Criteria | 1 | 2015 | 23 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2019 | 1577 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2017 | 374 | 0.030 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 1999 | 405 | 0.030 |
Why?
|
| Spinal Cord | 1 | 2016 | 255 | 0.030 |
Why?
|
| Lymphatic Irradiation | 1 | 2014 | 7 | 0.030 |
Why?
|
| Epidemiologic Methods | 1 | 2015 | 60 | 0.030 |
Why?
|
| Lymphoma, B-Cell | 1 | 1996 | 106 | 0.030 |
Why?
|
| Genes, APC | 1 | 1994 | 27 | 0.030 |
Why?
|
| Cell Nucleus | 1 | 1997 | 600 | 0.030 |
Why?
|
| Rotation | 1 | 2014 | 91 | 0.030 |
Why?
|
| Liposomes | 1 | 1994 | 93 | 0.030 |
Why?
|
| Surgical Instruments | 1 | 2014 | 57 | 0.030 |
Why?
|
| Transcription, Genetic | 1 | 1999 | 1160 | 0.030 |
Why?
|
| Paclitaxel | 2 | 2006 | 479 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2015 | 785 | 0.030 |
Why?
|
| Necrosis | 1 | 2014 | 210 | 0.030 |
Why?
|
| Self Concept | 1 | 2014 | 133 | 0.030 |
Why?
|
| Equipment Design | 1 | 2014 | 419 | 0.030 |
Why?
|
| Data Collection | 1 | 2014 | 375 | 0.030 |
Why?
|
| Adolescent | 2 | 2015 | 9289 | 0.020 |
Why?
|
| Internet | 1 | 2014 | 320 | 0.020 |
Why?
|
| Cervical Vertebrae | 1 | 2012 | 84 | 0.020 |
Why?
|
| Colon | 1 | 1994 | 511 | 0.020 |
Why?
|
| SEER Program | 1 | 2011 | 198 | 0.020 |
Why?
|
| Decision Making | 1 | 2016 | 668 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2011 | 272 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2011 | 372 | 0.020 |
Why?
|
| Neural Stem Cells | 1 | 2011 | 58 | 0.020 |
Why?
|
| Databases, Genetic | 1 | 2011 | 269 | 0.020 |
Why?
|
| Spiro Compounds | 1 | 2010 | 26 | 0.020 |
Why?
|
| Gene Expression | 1 | 1994 | 1310 | 0.020 |
Why?
|
| Drug Design | 1 | 2010 | 127 | 0.020 |
Why?
|
| Biological Transport | 1 | 2010 | 401 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2013 | 596 | 0.020 |
Why?
|
| Body Burden | 1 | 2008 | 9 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2014 | 1048 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2011 | 1276 | 0.020 |
Why?
|
| Leucovorin | 1 | 2006 | 224 | 0.020 |
Why?
|
| Mandibular Diseases | 1 | 2005 | 16 | 0.020 |
Why?
|
| Organ Specificity | 1 | 2006 | 273 | 0.020 |
Why?
|
| Osteoradionecrosis | 1 | 2005 | 18 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2012 | 1253 | 0.020 |
Why?
|
| Hydroxyurea | 1 | 2005 | 239 | 0.020 |
Why?
|
| Mastectomy, Radical | 1 | 2005 | 10 | 0.020 |
Why?
|
| DNA, Neoplasm | 1 | 2006 | 269 | 0.020 |
Why?
|
| Colonic Neoplasms | 1 | 2009 | 572 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2005 | 285 | 0.020 |
Why?
|
| Neuroectodermal Tumors | 1 | 2004 | 2 | 0.010 |
Why?
|
| Camptothecin | 1 | 2005 | 196 | 0.010 |
Why?
|
| Axilla | 1 | 2005 | 104 | 0.010 |
Why?
|
| Deoxycytidine | 1 | 2005 | 238 | 0.010 |
Why?
|
| DNA Damage | 1 | 2006 | 371 | 0.010 |
Why?
|
| Computer Simulation | 1 | 2008 | 1100 | 0.010 |
Why?
|
| Preoperative Care | 1 | 2006 | 395 | 0.010 |
Why?
|
| Survival | 1 | 2003 | 21 | 0.010 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2004 | 243 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2005 | 988 | 0.010 |
Why?
|
| Rats | 2 | 1998 | 4043 | 0.010 |
Why?
|
| Biotransformation | 1 | 1998 | 50 | 0.010 |
Why?
|
| Cell Death | 1 | 1999 | 262 | 0.010 |
Why?
|
| Light | 1 | 1998 | 293 | 0.010 |
Why?
|
| Adenoviridae | 1 | 1997 | 349 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1999 | 1944 | 0.010 |
Why?
|
| beta-Galactosidase | 1 | 1994 | 73 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 1994 | 1237 | 0.010 |
Why?
|
| Base Sequence | 1 | 1994 | 2329 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 1994 | 3027 | 0.010 |
Why?
|
| Intestinal Mucosa | 1 | 1994 | 805 | 0.010 |
Why?
|